In the absence of any observations of anti-tumorigenic-specific disruptions of DNMT1/protein-x interactions, we next analyzed whether the specific disruption of a DNMT1/protein-x interaction devoid of action on glioma-genesis could have an impact on the response to the standard GBM treatment combining temozolomide (TMZ) and irradiation. The gene discussed is PSMB5; the disease is glioma.